Novo’s Tresiba primed for key ‘hypo’ label update in EU
Fast-acting insulin also approved in US
Fast-acting insulin also approved in US
Danish pharma plans outcome trial to confirm benefits in SUSTAIN 6
Novo expects Victoza and semaglutide to gain momentum.
Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
Novo hopes data will justify higher price compared with rival.
Semaglutide is under review in Europe and US.
Unlike AZ’s Soriot, Schultz “couldn’t refuse” top job at Teva.